Literature DB >> 24107769

Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success.

John M Kane1.   

Abstract

Too many patients with schizophrenia do not achieve the ultimate goal of treatment-recovery. The first step to recovery is achieving response to treatment for the acute psychotic episode. Clinicians should routinely use rating scales to measure treatment response. The next phase is remission of symptoms, which is one of the criteria for recovery. Relapses, however, can disrupt remission and hinder recovery by causing rehospitalization, treatment resistance, and loss of gains in function. Medication adherence plays a major role in preventing relapses so that patients can maintain remission and work toward recovery. Clinicians should educate patients about adherence and consider treatment options that will improve adherence. Recovery is attained when patients experience symptom remission, vocational role fulfillment, independent living, and social relationships for at least 2 years. The proportion of patients who reach recovery can be increased when clinicians focus on treatment adherence, consistent symptom measurement, and appropriate treatment plans tailored to each patient. © Copyright 2013 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24107769     DOI: 10.4088/JCP.12117tx1c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

Review 1.  Actionable Adherence Monitoring: Technological Methods to Monitor and Support Adherence to Antiretroviral Therapy.

Authors:  Kate M Bell; Jessica E Haberer
Journal:  Curr HIV/AIDS Rep       Date:  2018-10       Impact factor: 5.071

2.  Paliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study.

Authors:  Rosaria Di Lorenzo; Michela Cameli; Marisa Bolondi; Giulia Landi; Valentina Moretti; Chiara Piemonte; Gabriella Pollutri
Journal:  Psychopharmacol Bull       Date:  2016-03-01

3.  Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments.

Authors:  Paul H Lysaker; Michelle L Pattison; Bethany L Leonhardt; Scott Phelps; Jenifer L Vohs
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

4.  Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.

Authors:  Clifton Blackwood; Panna Sanga; Isaac Nuamah; Alexander Keenan; Arun Singh; Maju Mathews; Srihari Gopal
Journal:  Patient Prefer Adherence       Date:  2020-07-02       Impact factor: 2.711

5.  Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.

Authors:  A Schreiner; P Bergmans; P Cherubin; S Keim; P-M Llorca; B Cosar; A Petralia; G Corrivetti; L Hargarter
Journal:  J Psychopharmacol       Date:  2015-05-21       Impact factor: 4.153

Review 6.  Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria.

Authors:  Brittany B Dennis; Pavel S Roshanov; Leen Naji; Monica Bawor; James Paul; Carolyn Plater; Guillaume Pare; Andrew Worster; Michael Varenbut; Jeff Daiter; David C Marsh; Dipika Desai; Zainab Samaan; Lehana Thabane
Journal:  Trials       Date:  2015-10-21       Impact factor: 2.279

Review 7.  Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia.

Authors:  Bernardo Carpiniello; Federica Pinna
Journal:  Drug Des Devel Ther       Date:  2016-05-24       Impact factor: 4.162

Review 8.  Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia.

Authors:  Maju Mathews; Srihari Gopal; Isaac Nuamah; Ludger Hargarter; Adam J Savitz; Edward Kim; Wilson Tan; Bernardo Soares; Christoph U Correll
Journal:  Neuropsychiatr Dis Treat       Date:  2019-05-21       Impact factor: 2.570

9.  Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics.

Authors:  Andrea de Bartolomeis; Andrea Fagiolini; Marco Vaggi; Claudio Vampini
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-11       Impact factor: 2.570

10.  Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.

Authors:  Tianmei Si; Nan Li; Huafei Lu; Shangli Cai; Jianmin Zhuo; Christoph U Correll; Lili Zhang; Yu Feng
Journal:  J Psychopharmacol       Date:  2018-05-16       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.